Skip to main content

Advertisement

SpringerLink
Log in

Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial

  • Original paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Background

Human herpesvirus type 8 (HHV-8), a gamma herpesvirus associated with Kaposi’s sarcoma, has been proposed as a candidate risk factor for prostate cancer (PCa) because of its detection in benign and malignant prostate specimens, and its relation with histologic prostatic inflammation. We investigated the possible relation between pre-diagnostic HHV-8 infection and PCa risk in a case–control study sampled from the placebo arm of the Prostate Cancer Prevention Trial.

Methods

We defined cases as men with a confirmed diagnosis of PCa after visit 2 (n = 315) and controls as men not diagnosed with PCa during the trial who also had a negative end-of-study prostate biopsy (n = 315). We tested sera from visit 2 for IgG antibodies against HHV-8 using a monoclonal antibody-enhanced immunofluorescence assay against multiple lytic HHV-8 antigens.

Results

The adjusted seroprevalence of HHV-8 infection was 11.6 % for cases and 11.0 % for controls (p = 0.81). No association was observed between HHV-8 seropositivity and PCa risk (OR 1.06, 95 % CI 0.65–1.76).

Conclusion

Our findings of a null association between HHV-8 seropositivity and PCa risk do not support an association between HHV-8 infection and PCa development, consistent with the general tendency of the epidemiologic literature to date.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boyle P, Levin B (2008) Chronic infections. World Cancer Report International Agency for Research on Cancer, Lyon, p 131

    Google Scholar 

  2. Monini P, de Lellis L, Fabris M, Rigolin F, Cassai E (1996) Kaposi’s sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen. N Engl J Med 334(18):1168–1172

    Article  CAS  PubMed  Google Scholar 

  3. Montgomery JD, Jacobson LP, Dhir R, Jenkins FJ (2006) Detection of human herpesvirus 8 (HHV-8) in normal prostates. Prostate 66(12):1302–1310

    Article  CAS  PubMed  Google Scholar 

  4. Corbellino M, Poirel L, Bestetti G, Pizzuto M, Aubin JT, Capra M et al (1996) Restricted tissue distribution of extralesional Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS patients with Kaposi’s sarcoma. AIDS Res Hum Retroviruses 12(8):651–657

    Article  CAS  PubMed  Google Scholar 

  5. Diamond C, Brodie SJ, Krieger JN, Huang ML, Koelle DM, Diem K et al (1998) Human herpesvirus 8 in the prostate glands of men with Kaposi’s sarcoma. J Virol 72(7):6223–6227

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Capuano M, La Parola IL, Cattani P, Cerimele F, Sasso F, Masini C et al (1998) Kaposi’s sarcoma associated herpesvirus deoxyribonucleic acid sequences: lack of detection in prostatic tissue of human immunodeficiency virus-negative immunocompetent adults. J Urol 160(2):505–506

    Article  CAS  PubMed  Google Scholar 

  7. Pauk J, Huang ML, Brodie SJ, Wald A, Koelle DM, Schacker T et al (2000) Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 343(19):1369–1377

    Article  CAS  PubMed  Google Scholar 

  8. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG et al (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7(4):256–269

    Article  PubMed Central  PubMed  Google Scholar 

  9. Hoffman LJ, Bunker CH, Pellett PE, Trump DL, Patrick AL, Dollard SC et al (2004) Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer. J Infect Dis 189(1):15–20

    Article  PubMed  Google Scholar 

  10. Korodi Z, Wang X, Tedeschi R, Knekt P, Dillner J (2005) No serological evidence of association between prostate cancer and infection with herpes simplex virus type 2 or human herpesvirus type 8: a nested case–control study. J Infect Dis 191(12):2008–2011

    Article  PubMed  Google Scholar 

  11. Jenkins FJ, Hayes RB, Jackson A, Pizza G, Mbisa G, Whitby D et al (2007) Human herpesvirus 8 seroprevalence among prostate cancer case patients and control subjects. J Infect Dis 196(2):208–211

    Article  CAS  PubMed  Google Scholar 

  12. Sutcliffe S, Giovannucci E, Gaydos CA, Viscidi RP, Jenkins FJ, Zenilman JM et al (2007) Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomark Prev 16(8):1573–1580

    Article  CAS  Google Scholar 

  13. Huang WY, Hayes R, Pfeiffer R, Viscidi RP, Lee FK, Wang YF et al (2008) Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol Biomark Prev 17(9):2374–2381

    Article  CAS  Google Scholar 

  14. McDonald AC, Jenkins FJ, Bunker CH, Wilson JW, Patrick AL, Weissfeld JL (2011) A case–cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago. Infect Agent Cancer 6:25

    Article  PubMed Central  PubMed  Google Scholar 

  15. Ge X, Wang X, Shen P (2013) Herpes simplex virus type 2 or human herpesvirus 8 infection and prostate cancer risk: a meta-analysis. Biomed Rep 1(3):433–439

    CAS  PubMed Central  PubMed  Google Scholar 

  16. Goodman PJ, Tangen CM, Crowley JJ, Carlin SM, Ryan A, Coltman CA Jr et al (2004) Implementation of the prostate cancer prevention trial (PCPT). Control Clin Trials 25(2):203–222

    Article  PubMed  Google Scholar 

  17. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3):215–224

    Article  CAS  PubMed  Google Scholar 

  18. Lennette ET, Blackbourn DJ, Levy JA (1996) Antibodies to human herpesvirus type 8 in the general population and in Kaposi’s sarcoma patients. Lancet 348(9031):858–861

    Article  CAS  PubMed  Google Scholar 

  19. Spira TJ, Lam L, Dollard SC, Meng YX, Pau CP, Black JB et al (2000) Comparison of serologic assays and PCR for diagnosis of human herpesvirus 8 infection. J Clin Microbiol 38(6):2174–2180

    CAS  PubMed Central  PubMed  Google Scholar 

  20. Pellett PE, Wright DJ, Engels EA, Ablashi DV, Dollard SC, Forghani B et al (2003) Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion 43(9):1260–1268

    Article  CAS  PubMed  Google Scholar 

  21. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF et al (2008) Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 167(8):925–934

    Article  PubMed  Google Scholar 

  22. Sutcliffe S, Alderete JF, Till C, Goodman PJ, Hsing AW, Zenilman JM et al (2009) Trichomonosis and subsequent risk of prostate cancer in the prostate cancer prevention trial. Int J Cancer 124(9):2082–2087

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Sutcliffe S, Viscidi RP, Till C, Goodman PJ, Hoque AM, Hsing AW et al (2010) Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev 19(2):614–618

    Article  CAS  Google Scholar 

  24. Sutcliffe S, Till C, Gaydos CA, Jenkins FJ, Goodman PJ, Hoque AM et al (2012) Prospective study of cytomegalovirus serostatus and prostate cancer risk in the prostate cancer prevention trial. Cancer Causes Control 23(9):1511–1518

    Article  PubMed Central  PubMed  Google Scholar 

  25. Franceschi S, Geddes M (1995) Epidemiology of classic Kaposi’s sarcoma, with special reference to mediterranean population. Tumori 81(5):308–314

    CAS  PubMed  Google Scholar 

  26. Dukers NH, Rezza G (2003) Human herpesvirus 8 epidemiology: what we do and do not know. Aids 17(12):1717–1730

    Article  PubMed  Google Scholar 

  27. Engels EA, Atkinson JO, Graubard BI, McQuillan GM, Gamache C, Mbisa G et al (2007) Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis 196(2):199–207

    Article  PubMed  Google Scholar 

  28. Mygatt JG, Singhal A, Sukumar G, Dalgard CL, Kaleeba JA (2013) Oncogenic herpesvirus HHV-8 promotes androgen-independent prostate cancer growth. Cancer Res 73(18):5695–5708

    Article  CAS  PubMed  Google Scholar 

  29. Sitas F, Carrara H, Beral V, Newton R, Reeves G, Bull D et al (1999) Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med 340(24):1863–1871

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank the technicians from the PCPT Pathology and Genotyping Core directed by M. Scott Lucia for their efforts in providing serum specimens for testing, Britteny Zeher for HHV-8 antibody testing, the Baltimore City Health Department (Dr. Emily J. Erbelding, Vincent Marsiglia and Sarah Norman) for generous provision of quality control serum specimens, and Dr. Catherine M. Tangen for general statistical discussions. This project was funded by research Grants P01 CA108964 (Biology of the PCPT) and U01 CA37429 from the National Cancer Institute, National Institutes of Health, as well as the Barnes-Jewish Hospital Foundation. The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author information

Authors and Affiliations

  1. Division of Public Health Sciences, Department of Surgery, The Alvin J. Siteman Cancer Center, Washington University School of Medicine, 660 S. Euclid Ave., Box 8100, Rm. 208S, St. Louis, MO, 63110, USA

    Siobhan Sutcliffe

  2. SWOG Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Cathee Till & Phyllis J. Goodman

  3. Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

    Frank J. Jenkins

  4. Departments of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA

    Frank J. Jenkins

  5. Division of Infectious Diseases, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA

    Charlotte A. Gaydos

  6. University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    Ashraful M. Hoque

  7. Cancer Prevention Institute of California, Fremont, CA, USA

    Ann W. Hsing

  8. Stanford Cancer Institute, Stanford University, Palo Alto, CA, USA

    Ann W. Hsing

  9. Division of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    Ian M. Thompson

  10. Departments of Oncology and Pharmacology, Johns Hopkins Medical Institutions, Baltimore, MD, USA

    William G. Nelson

  11. Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA

    William G. Nelson & Angelo M. De Marzo

  12. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA

    William G. Nelson, Angelo M. De Marzo & Elizabeth A. Platz

  13. James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA

    William G. Nelson, Angelo M. De Marzo & Elizabeth A. Platz

  14. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Elizabeth A. Platz

Authors
  1. Siobhan Sutcliffe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cathee Till
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank J. Jenkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charlotte A. Gaydos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Phyllis J. Goodman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ashraful M. Hoque
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ann W. Hsing
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ian M. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. William G. Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Angelo M. De Marzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Elizabeth A. Platz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Siobhan Sutcliffe.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sutcliffe, S., Till, C., Jenkins, F.J. et al. Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control 26, 35–44 (2015). https://doi.org/10.1007/s10552-014-0480-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-014-0480-5

Keywords

Search

Navigation